Their stake was purchased from Biggar, a charitable foundation that is said to be ThromboGenics’s largest shareholder.
Biggar now holds a 9.8% stake in ThromboGenics following this transaction, and has informed the company that it intends to remain an important shareholder in ThromboGenics for the long term. This transaction was managed by Petercam.
Desire Collen, chairman and CEO of ThromboGenics, said: “We are very pleased that we have been able to attract such a group of high net worth individuals to become shareholders in ThromboGenics, particularly given their long term commitment to the company.”